HC Wainwright & Co. Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $50
Ultragenyx Pharmaceutical, Inc. +2.48% Pre
Ultragenyx Pharmaceutical, Inc. RARE | 25.18 25.18 | +2.48% 0.00% Pre |
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ultragenyx Pharmaceutical (NASDAQ:
RARE) with a Buy and lowers the price target from $60 to $50.
